Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-05 |
mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0001 |
mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0007 |
mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.096 | 0.002 |
mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |